Philip Kantoff's most recent trade in Context Therapeutics Inc was a trade of 45,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 24, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Context Therapeutics Inc | Philip Kantoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2026 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Context Therapeutics Inc | Philip Kantoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 123,500 | 123,500 | - | - | Stock Option (right to buy) | |
| Context Therapeutics Inc | Philip Kantoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Essa Pharma Inc | Philip Kantoff | Director | 25 Mar 2024 | 50,000 | 50,000 | - | - | Options | ||
| Context Therapeutics Inc | Philip Kantoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Context Therapeutics Inc | Philip Kantoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) |